Medical cannabis myths vs the evidence

Few areas of medicine attract as much overstatement as cannabis. A great deal of what circulates online is preclinical (cell cultures and animal studies), mechanistic, or simply anecdotal — yet it's often presented as settled fact. Here we take ten common claims and check them against the actual evidence.

Myth 1: "Cannabis is a proven treatment for almost anything"

The reality is far narrower. Robust human randomised-trial evidence exists for only a handful of uses. The genuinely strong evidence is for purified CBD in rare childhood epilepsies, and THC-based products for chemotherapy nausea. New Zealand's clinical guidance states plainly that there is "currently insufficient clinical trial evidence to support medicinal cannabis products being used first-line for any indication."

Myth 2: "CBD works by activating the same receptors as THC"

It doesn't. CBD does not meaningfully activate CB1's main binding site. Its pharmacology is "promiscuous," touching dozens of different targets — serotonin receptors, TRP channels, and acting as a negative allosteric modulator at CB1. That's part of why it's non-intoxicating.

Myth 3: "CBD cancels out THC, so balanced products are always safe"

An oversimplification. CBD can blunt some of THC's unwanted effects, but it's dose- and route-dependent and not absolute. One controlled study of edibles found CBD did not reliably reduce — and on some measures increased — THC's adverse effects.

Myth 4: "CBN is a powerful sleep aid"

Largely a myth. The belief traces to anecdote and a roughly 50-year-old rat study; human data are essentially absent. CBN is a weak breakdown product of THC, not a proven sedative.

Myth 5: "Myrcene makes indicas sedating — the couch-lock effect"

This popular "rule" has no peer-reviewed basis. It traces back to an uncited blog post. The whole indica/sativa-equals-effect framework is far shakier than marketing implies.

Myth 6: "The entourage effect is established science"

It's a plausible, actively studied hypothesis — not a validated clinical fact. A comprehensive review states there are "no clinical trials specifically designed to validate the entourage effect." The term is often used for marketing. One narrow human finding stands out: the terpene D-limonene reduced THC-induced anxiety in a controlled trial — a single specific interaction, not broad synergy.

Myth 7: "Cannabis is natural, so it's safe"

Natural doesn't mean harmless. Around four in five people on a medicinal cannabis product experience some side effect. THC can cause anxiety, paranoia and a fast heart rate, and in vulnerable people can trigger or worsen psychosis. Cannabis interacts with common medicines and is generally inappropriate in pregnancy.

Myth 8: "A prescription means I can drive normally"

No. New Zealand's roadside drug testing can still detect THC and trigger an automatic driving ban; a prescription is only a retrospective medical defence, and it's always illegal to drive impaired.

Myth 9: "Vaporising is completely safe"

Safer than smoking, but not risk-free. Vaporising avoids combustion byproducts, but at high temperatures terpenes can degrade into irritants. Lower vaporiser temperatures are preferable.

Myth 10: "Cannabis cures cancer"

There is no good human evidence that cannabis cures cancer. Some cannabinoids show anti-tumour effects in the laboratory, but that has not translated into proven treatment in people. Presenting cannabis as a cancer cure is both false and potentially dangerous if it delays effective care.

Myth 11: "Indica vs sativa tells you the effect"

The familiar indica-equals-relaxing, sativa-equals-energising split is far less reliable than marketing suggests. The categories describe the plant's appearance and lineage more than its chemistry, and modern cultivars are heavily hybridised. The actual effects depend on the cannabinoid content (THC and CBD levels and ratio) and dose far more than on a label. Two "indica" products can behave quite differently. Focus on the cannabinoid profile your prescriber recommends, not the strain name.

Myth 12: "More THC is always more effective"

Not so — and often the opposite. THC has biphasic effects: low doses can be calming, while higher doses can provoke anxiety, paranoia and a fast heart rate. The dosing literature is clear that euphoria isn't required for symptom relief, and overshooting the dose tends to add side effects, not benefit. This is exactly why "start low, go slow" is the standard approach. More is not better; the lowest effective dose is the target.

Why so much misinformation?

Part of the reason cannabis attracts so many myths is commercial: in markets where products can be marketed, strong claims sell. Part is structural — much of the published research is preclinical, and it's easy to dress up a promising mouse study as a human breakthrough. And part is the genuine, understandable hope of people seeking relief. None of this is sinister, but it means the burden is on the reader to be sceptical and to weight human trial evidence over lab findings and testimonials.

How to read cannabis claims

A few habits protect you from hype: ask whether a claim is based on human trials or just lab and animal studies; be wary of anything that sounds like marketing ("miracle," "cure," "entourage"); check whether reputable bodies (Cochrane, the National Academies, bpacnz) agree; and remember that the absence of strong evidence isn't proof something doesn't work — it just means we don't yet know. Honest uncertainty is the correct posture for much of cannabis medicine.

Last reviewed 14 September 2026 — education, not medical advice. Sources: bpacnz; Entourage effect review (PMC11870048); Corroon 2021 — CBN.